Nitinotes gets FDA green light for U.S. obesity treatment trial

Israeli medtech firm Nitinotes received FDA approval to begin a key U.S. trial of its EndoZip™ system, a new device for treating obesity with a less invasive procedure called endoscopic sleeve gastroplasty (ESG), according to the Press Service of Israel (TPS-IL).

The trial will include up to 184 patients at 10 U.S. sites and is expected to start later this year. EndoZip uses automated suturing to make the procedure easier and more consistent. CEO Lloyd Diamond said the approval brings the company closer to offering the treatment in the U.S. A European launch is also in the works.